# OnCo record nct07413939 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07413939/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07413939", "NCT07413939" ;
  schema:name "RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive"@en ;
  schema:alternateName "BREnnA"@en ;
  schema:description "A phase 2/3 trial testing RO7771950 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07413939/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07413939> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2026-05-21" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:drugs <https://onco.cc/drugs/ro7771950/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> .